Search Results

You are looking at 1 - 1 of 1 items for

  • Author: F U S Mattace-Raso x
Clear All Modify Search
V G Pluimakers Princess Máxima Centre for Paediatric Oncology, Utrecht, The Netherlands

Search for other papers by V G Pluimakers in
Google Scholar
PubMed
Close
,
M van Waas Department of Paediatric Oncology/Haematology, Erasmus MC–Sophia Children’s Hospital, Rotterdam, The Netherlands

Search for other papers by M van Waas in
Google Scholar
PubMed
Close
,
C W N Looman Department of Public Health, Erasmus MC, Rotterdam, The Netherlands

Search for other papers by C W N Looman in
Google Scholar
PubMed
Close
,
M P de Maat Department of Haematology, Erasmus MC, Rotterdam, The Netherlands

Search for other papers by M P de Maat in
Google Scholar
PubMed
Close
,
R de Jonge Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands

Search for other papers by R de Jonge in
Google Scholar
PubMed
Close
,
P Delhanty Section Endocrinology, Department of Medicine, Erasmus MC, Rotterdam, The Netherlands

Search for other papers by P Delhanty in
Google Scholar
PubMed
Close
,
M Huisman Section Endocrinology, Department of Medicine, Erasmus MC, Rotterdam, The Netherlands

Search for other papers by M Huisman in
Google Scholar
PubMed
Close
,
F U S Mattace-Raso Section Geriatric Medicine, Department of Medicine, Erasmus MC, Rotterdam, The Netherlands

Search for other papers by F U S Mattace-Raso in
Google Scholar
PubMed
Close
,
M M van den Heuvel-Eibrink Princess Máxima Centre for Paediatric Oncology, Utrecht, The Netherlands

Search for other papers by M M van den Heuvel-Eibrink in
Google Scholar
PubMed
Close
, and
S J C M M Neggers Princess Máxima Centre for Paediatric Oncology, Utrecht, The Netherlands
Section Endocrinology, Department of Medicine, Erasmus MC, Rotterdam, The Netherlands

Search for other papers by S J C M M Neggers in
Google Scholar
PubMed
Close

Purpose:

Augmented survival of childhood nephroblastoma and neuroblastoma has increased long-term side effects such as metabolic syndrome (MetS). Risk stratification is difficult after abdominal radiation because waist circumference underestimates adiposity. We aimed to develop a strategy for determining MetS in irradiated survivors using an integrated biomarker profile and vascular ultrasonography.

Methods:

The NCEP-ATPIII MetS-components, 14 additional serum biomarkers and 9 vascular measurements were assessed in a single-centre cohort of childhood nephroblastoma (n = 67) and neuroblastoma (n = 36) survivors and controls (n = 61). Multivariable regression models were used to study treatment effects. Principal component analysis (PCA) was used to study all biomarkers in a combined analysis, to identify patterns and correlations.

Results:

After 27.5 years of follow-up, MetS occurred more often in survivors (14%) than controls (3%). Abdominal radiotherapy and nephrectomy, to a lesser extent, were associated with MetS and separate components and with several biomarker abnormalities. PCA of biomarkers revealed a pattern on PC1 from favourable lipid markers (HDL-cholesterol, adiponectin) towards unfavourable markers (triglycerides, LDL-cholesterol, apoB, uric acid). Abdominal radiotherapy was associated with the unfavourable biomarker profile (β = 1.45, P = 0.001). Vascular measurements were not of added diagnostic value.

Conclusions:

Long-term childhood nephro- and neuroblastoma survivors frequently develop MetS. Additional assessment of biomarkers identified in PCA – adiponectin, LDL, apoB, and uric acid – may be used especially in abdominally irradiated survivors, to classify MetS as alternative for waist circumference. Vascular ultrasonography was not of added value.

Open access